New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Revolutionizing Atopic Dermatitis

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

2025 American Thoracic Society (ATS) International Conference

 suggest that methotrexate may be considered an effective alternative treatment to prednisone for pulmonary sarcoidosis.

Although prednisone is widely considered to be the initial therapy for 

, its implementation is known to be commonly accompanied by different adverse effects. In the new findings presented at the ATS 2025 International Conference, during a session titled "Advances in the Diagnosis and Management of ILD," the results suggest that methotrexate may serve as an effective alternative, with similar disease control and potentially fewer side effects.

“The results of this trial show that methotrexate can be offered as an alternative for prednisone for patients with pulmonary sarcoidosis,” first author Vivienne Kahlmann, MD, a pulmonologist in training at Erasmus Medical Center in the Netherlands, said in a statement.

Sarcoidosis is an immune-mediated disorder that is known to be multifaceted, with a highly unpredictable trajectory. Some patients with the condition improve without treatment, whereas others may need immunosuppression to preserve their organ function and to improve their quality of life. Although prednisone is the standard-of-care based on international recommendations, the guidelines were not established via randomized clinical trial data.

Prednisone’s efficacy can have a cost, with undesirable symptoms such as sleep issues, weight gain, and mood shifts having been reported. Its prolonged utilization among patients also potentially raises the risk of long-term complications.

Kahlmann and colleagues’ analysis of methotrexate as an alternative to prednisone was the first randomized controlled trial that made direct comparisons with both of these 2 therapies for pulmonary sarcoidosis. The investigative team involved 17 hospitals in this collaborative study in the Netherlands.

The study was titled PREDMETH, with 137 individuals enrolled as subjects, 69 of whom were treated with prednisone and 68 were given methotrexate.

 Overall, the investigators concluded that methotrexate was shown to be non-inferior to prednisone in the management of pulmonary sarcoidosis over a 24-week period. Methotrexate, on the other hand, was shown by the coauthors to have demonstrated a slower onset but to be ultimately as effective by the 24-week mark.

Kahlmann et al highlighted that while the overall frequency of adverse events was comparable between the 2 cohorts, those in the methotrexate arm of the analysis reported fewer persistent side effects by the study’s conclusion. They noted the differences in both treatments’ side effect profiles: prednisone showed a more common association with insomnia, appetite increases, and weight gain, whereas those in the methotrexate arm more commonly reported fatigue, nausea, and liver enzyme abnormalities.

“Results were in line with what we hypothesized,” study co-author Marlies Wijsenbeek, MD, a pulmonologist at the Erasmus Medical Center, said in a statement.

 “It was, however, surprising to see that some symptom scores already improved after four weeks of treatment in the methotrexate group.”

Future directions for the investigative team include developing a clinical decision-support tool to aid in the shared decision-making process between clinicians and patients, as well as conducting follow-up analyses. These will include biomarker analyses from blood samples gathered during the course of this analysis to help predict individual treatment responses.

Newswise. Methotrexate as Effective as Prednisone in Pulmonary Sarcoidosis. American Thoracic Society. May 18, 2025. Accessed May 18, 2025. 

https://www.newswise.com/articles/methotrexate-as-effective-as-prednisone-in-pulmonary-sarcoidosis

Kahlmann V, Wijsenbeek M, et al. Methotrexate Versus Prednisone as First-line Treatment for Pulmonary Sarcoidosis: The PREDMETH Trial. Abstract presented at the American Thoracic Society (ATS) International Conference 2025 in San Francisco, CA, from May 18 - May 21, 2025.

Articles

New research from the 2025 ATS International Conference indicates methotrexate as a viable alternative to prednisone for pulmonary sarcoidosis, offering similar disease control with potentially fewer side effects. The PREDMETH trial, a randomized controlled study involving 137 participants, demonstrated methotrexate's non-inferiority to prednisone over 24 weeks. While both treatments had comparable adverse event frequencies, methotrexate showed fewer persistent side effects. Future research aims to develop a clinical decision-support tool and conduct biomarker analyses to predict individual treatment responses.

These data, presented at ATS 2025, highlight the efficacy results of methotrexate when compared to prednisone for pulmonary sarcoidosis.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Methotrexate Effective as Alternative to Prednisone for Pulmonary Sarcoidosis

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Waitlist outcomes have significantly improved since the implementation of new allocation guidelines for 

 that prioritize medical urgency, according to findings from a recent study.

the American Thoracic Society (ATS) International Conference 2025

 and highlight improved outcomes following the implementation of United Network for Organ Sharing (UNOS) Composite Allocation Score (CAS) in 2023, especially among the sickest patients awaiting lung transplantation.

Recent years have seen several changes in donor lung allocation in an effort to improve fairness and waitlist outcomes. Prior to November 2017, donor organs were allocated locally before being offered beyond the OPO. After a lawsuit in 2017, the allocation unit expanded to 250 nautical miles and the United Network for Organ Sharing (UNOS)/Organ Procurement and Transplantation Network began designing a new continuous allocation system. In March 2023, UNOS implemented the CAS to help consider patient factors when determining allocation of donor lungs.

“We always want to make sure that any time we make a change to the allocation system that we’re improving outcomes, especially for our sickest patients,” first author Mary Raddawi, MD, said in a press release.

 “This provides confirmation that we’re on the right track.”

Raddawi and colleagues conducted a retrospective cohort study using the UNOS registry. They created 3 cohorts from the 24,368 patients listed since February 19, 2015: Pre-November 2017 era (Cohort 1), post-November 2017 era (November 2017 - March 2023; Cohort 2) and CAS era (March 2023 - March 2024; Cohort 3). They additionally categorized patients into groups based on the waitlist urgency (WLU) score at listing: the top 5% WLU, use of High-flow nasal-cannula (HFNC) and bottom 25% of medical WLU.

In the pre-November 2017 era, 11.2% of patients on the waitlist died/delisted, compared with 8.4% in the post-November 2017 era and 4.1% in the CAS era. In patients with the top 5% of WLU scores at listing, 34.5% of patients died/delisted in the pre-November 2017 era, compared with 22.2% in the post-November 2017 era and 6.5% in the CAS era.

In an adjusted model, the pre- and post-November 2017 eras were associated with 3.3-fold and 2.1-fold increased risk of death/delisting compared to the CAS era (sHR, 3.32; 95% CI, 2.74-4.02; 

<.001). For patients in the top 5% of WLU at listing, investigators noted the pre- and post-November 2017 eras were associated with 8-fold and 4.8-fold increased risks of death/delisting compared to the CAS era (sHR, 7.97; 95% CI, 3.72-17.1; 

Investigators also pointed out patients on HFNC at listing had an increased risk of death/delisting in the prior eras compared to the CAS era (sHR, 7.68; 95% CI, 5.54-10.64; 

“When you think about the fact that now we’re focusing on many different factors, including medical urgency, it makes sense that the waitlist mortality would go down for our sicker patients — but it is nice to see the actual numbers,” Raddawi said.

Raddawi M, Laothamatas K, Grewal HS, et al. Improvement in Wait List Mortality for the Most Critically Ill Since the Implementation of the CAS. Abstract presented at the American Thoracic Society (ATS) International Conference 2025 in San Francisco, CA, from May 18 - May 21, 2025.

UNOS. Lung Composite Allocation Score (CAS) calculator available on OPTN website. February 2, 2023. Accessed May 18, 2025. 

https://unos.org/news/lung-composite-allocation-score-cas-calculator-available-on-optn-website/

Newswise. Waitlist Deaths Dropped Under New Lung Transplant Allocation System. American Thoracic Society. May 18, 2025. Accessed May 18, 2025. 

https://www.newswise.com/articles/waitlist-deaths-dropped-under-new-lung-transplant-allocation-system

The implementation of the Composite Allocation Score (CAS) by the United Network for Organ Sharing (UNOS) in 2023 has significantly improved waitlist outcomes for lung transplants, particularly for the most critically ill patients. A retrospective cohort study revealed a marked decrease in waitlist mortality rates across different eras, with the CAS era showing the lowest rates. The study categorized patients based on waitlist urgency scores and highlighted the reduced risk of death or delisting in the CAS era compared to previous allocation systems, emphasizing the importance of prioritizing medical urgency.

New research sheds light on improved waitlist outcomes after new allocation guidelines for lung transplants prioritizing medical urgency were implemented.

Lung Transplant Waitlist Outcomes Improved After 2023 Allocation System Change

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

At the 2025 New Wave Dermatology meeting in Aventura, Florida, Matthew Zirwas, MD, a dermatologist at Bexley Dermatology, presented on the most useful 

The studies spanned across dermatologic diseases—hidradenitis suppurativa, burning mouth syndrome, contact dermatitis, atopic dermatitis, psoriasis, hair loss, vitiligo, and melasma. In an on-site interview with HCPLive, Zirwas shared the 

top 5 most useful dermatology journal entries published in the past 2 years

. He highlighted a 2025 retrospective study that explained why 2 out of 3 people with atopic dermatitis are misdiagnosed.1

The study showed the difference between pediatric and adult atopic dermatitis, which explains the ineffectiveness of Hanafin and Rajka criteria for diagnosing adult atopic dermatitis. Genetics causes atopic dermatitis in children, but skin damage causes atopic dermatitis in adults.

However, during his presentation, Zirwas described many other useful journal entries:

Efficacy of Strontium Cream in Alleviating Pruritus in Hidradenitis Suppurativa

This recent open-label study demonstrated Dermeleve’s effectiveness in 75% of people. Although many burned with the application, 85% of participants said they would recommend it to others.

Topical Gabapentin Solution for the Management of Burning Mouth Syndrome: a Retrospective Study

This study explored gabapentin syrup, with patients instructed to swish and spit 3 times a day.

Impact of Dupilumab on Patch-Test Results and Allergic Contact Dermatitis: a Prospective Multicenter Study

A new study this year found dupilumab does not affect patch test reactions to any allergens, with zero reports of dupilumab actually working in contact dermatitis. However, dupilumab works great for patients with atopic dermatitis.

Discrepancies in Patch Testing Timing and Outcomes: A Retrospective Analysis of the Pediatric Allergic Contact Dermatitis Registry

Persulphates Allergic Contact Dermatitis from Spa: A New Aetiology of Nummular Contact Dermatitis

North American Contact Dermatitis Group Patch Test Results 2019 - 2020

Real-Life Management of Atopic Dermatitis Patients With an Inadequate Response to On-label Use of Dupilumab

This study showed an inadequate response to atopic dermatitis biologics like dupilumab. Zirwas said he still applies topical steroids 5 – 20% of the time. The study suggests adding a biologic or JAK inhibitor long-term is not a real option.

Dermatologists should consider short-term cyclosporine or JAK to calm atopic dermatitis and hope dupilumab will maintain improvement. They could also add an oral roflumilast 500 μg per day or methotrexate 5-10 mg per week. If dupilumab still doesn’t work, switching drugs may be necessary.

Diagnostic Accuracy of Patch Testing Based on Clinical Response to Contact Allergen Restrictions in Allergic Contact Dermatitis

In 2024, a study found that among 265 patients with a positive patch test for contact dermatitis, 41% had gotten at least 50% better. Only 10.5% improved by at least 90%.

These findings suggest dermatologists should not treat patch tests as diagnostic tools but rather like ANA testing, since it is good for ruling out contact dermatitis when negative.

Efficacy and Safety of Topical Corticosteroid Treatment Under Occlusion for Severe Alopecia Areata in Children: a Single-centre Retrospective Analysis

Oral JAK inhibitors work for about 1 in 5 patients with alopecia universalis or totalis. Dermatologists could consider adding prednisone to JAK: 20 mg/day x 30 days, 10 mg/day x 30 days, 5 mg/day x 30 days. There’s a risk of immunosuppression in the first month, so Zirwas recommends JAK for 6 months and adding prednisone if that regimen doesn’t work.

You can also try clobetasol ointment QHS under a swim cap; after good regrowth, return to a JAK inhibitor. If it still doesn’t work, stop after 6 months.

Low-Dose oral minoxidil initiation for patients with hair loss: an international modified Delphi consensus statement

Efficacy of topical finasteride 0.25% with minoxidil 5% vs topical minoxidil 5% alone in treatment of male pattern androgenic alopecia

Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series

Low-Dose Metformin and Profibrotic Signature in Central Centrifugal Cicatricial Alopecia

Effects of Oral Minoxidil on Nails: a Cross-sectional Analysis

Treatments for patients with brittle, slow-growing nails include biotin 1 mg + pyridoxine 100 mg, minoxidil orally (1.25 mg per day) or topically (5% to cuticles nightly), and cynatine HNS oral daily (available on Amazon), which improves hardness, thickness, and appearance.

Before applying ruxolitinib, consider genetic bimatoprost drops and add NBUVB if possible. Hydroxychloroquine 200 mg once daily was seen to be better than NBUVB in a trial.

The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study

Effectiveness, Tolerability, and Safety of Topical Clobetasol with Oral Hydroxychloroquine versus Topical Clobetasol of NBUVB Phototherapy in Unstable Vitiligo: Investigator Blind, Randomized Controlled Trial

Red light therapy should be used for 20 minutes once a week for androgenic alopecia, 12 minutes twice a day for skin aging. The wavelength should be in the 630 nm range.

Reverse Skin Aging Signs by Red Light Photobiomodulation

Red and Green LED Light Therapy: A Comparative Study in Androgenetic Alopecia

Studies have shown metformin helps acne, hidradenitis, CCCA, and reduces the risk of skin cancer. It is extremely safe and cheap, with no hypoglycemia risk.

Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study

Efficacy of metformin vs. doxycycline in treating acne vulgaris: An assessor-blinded, add-on, randomized, controlled clinical trial

Other Studies Mentioned During the Session:

Comparative analysis of switching strategies for IL-23 and IL-17A inhibitors for the treatment of psoriasis: Interclass switching outperforms intraclass switching

Final Clinical Diagnosis in Cases of Histopathologic Psoriasiform Dermatitis: Retrospective Cross-Sectional Analysis of a Southeastern United States population, 2004 - 2017

Therapeutic Efficacy and Safety of Oral Tranexamic Acid 250 mg Once a Day Versus 500 mg Twice a Day: A Comparative Study

Munayco Maldonado G, Foy V, Tai H, Chiesa Fuxench ZC. Variation in clinical presentation of pediatric-onset and adult-onset atopic dermatitis: a retrospective, single-center, chart review of adults with atopic dermatitis from the United States. 

. 2024;316(7):409. Published 2024 Jun 15. doi:10.1007/s00403-024-03008-x

Matthew Zirwas, MD, presented significant dermatology journal entries from the past year at the 2025 New Wave Dermatology meeting. Key studies covered a range of dermatologic conditions, including atopic dermatitis, hidradenitis suppurativa, burning mouth syndrome, and alopecia areata. Notably, a retrospective study highlighted misdiagnosis issues in atopic dermatitis due to differences between pediatric and adult forms. Other studies explored treatments like strontium cream for pruritus, topical gabapentin for burning mouth syndrome, and the impact of dupilumab on contact dermatitis. Zirwas also discussed management strategies for atopic dermatitis and alopecia areata.

At 2025 New Wave Dermatology, Zirwas highlights the most useful dermatology studies from the past 2 years, covering AD misdiagnosis, alopecia, contact dermatitis, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

The Top Dermatology Journal Entries in the Past 2 Years

The Top 5 Atopic Dermatitis Studies in the Past 2 Years, with Matthew Zirwas, MD

Top 5 Atopic Dermatitis Studies in the Past 2 Years, with Matthew Zirwas, MD

 studies have been published in the past 2 years, but which ones are the most useful to dermatologists?

At the 2025 New Wave Dermatology meeting in Aventura, Florida, Matthew Zirwas, a dermatologist at Bexley Dermatology, presented the most useful dermatology journal entries in the past year.

 He reviewed dermatologic uses for metformin, potential mechanisms of pimozide in delusions of parasitosis, ways to boost JAK inhibitor response in alopecia totalis, and treatments for burning mouth syndrome.

sat down with Zirwas at the meeting to discuss these highlights and his other talk on how to streamline the 

first 4 visits when diagnosing spongiotic dermatitis

. He also shared his picks for the top 5 atopic dermatitis studies published in the past 2 years.

“There have been some incredibly interesting new things, especially around atopic dermatitis,” Zirwas said. “[The most important finding is] that we are terrible at diagnosing it. As dermatology providers, we misdiagnose 2 out of 3 people who have atopic dermatitis. Instead of calling it atopic dermatitis, we're diagnosing it as dermatitis, unspecified. That needs to stop.”

Zirwas explained that adult atopic dermatitis is often misdiagnosed because the wrong criteria are used. While the Hanafin and Rajka criteria from the 1980s work well for children, they fall short in adults. Instead, he said dermatologists should follow the American Academy of Dermatology guidelines.

The difference lies in pathogenesis: genetics drive pediatric atopic dermatitis, but skin damage underlies adult cases. Zirwas pointed to toluene diisocyanate (TDI), a chemical in car exhaust and nylon and polyester clothing, as a major factor for skin damage.

“That explains why atopic dermatitis has been becoming more common, particularly since the 1970s, because the 1970s car exhaust changed to start to have this TDI in it, and that was because they put catalytic converters on cars,” Zirwas said. “Second, nylon and polyester became much more common in clothing, and residual TDI in nylon and polyester clothing is the other big driving factor for this acquired atopic dermatitis.”

Variation in clinical presentation of pediatric-onset and adult-onset atopic dermatitis: a retrospective, single-center, chart review of adults with atopic dermatitis from the United States

This retrospective review compared clinical features of adult- vs pediatric-onset AD. Adults had less flexural involvement and more nummular eczema and extensor surface involvement, with fewer personal or family histories of atopic disease.

Exposure to isocyanates predicts atopic dermatitis prevalence and disrupts therapeutic pathways in commensal bacteria

This study identified diisocyanates as strong predictors of atopic dermatitis. These chemicals disrupt beneficial lipid production and therapeutic modeling of 

 and commensal Staphylococcus. Diisocyanates demonstrated a temporospatial and epidemiological association with atopic dermatitis.

The 2023 Annual Report of DataDerm: The database of the American Academy of Dermatology

DataDerm, the American Academy of Dermatology’s massive dermatology database, included data from 14.2 million unique patients and 53.5 million visits in 2022. This report analyzed longitudinal care patterns for common dermatologic conditions, with emphasis on skin cancer.

Cohort studies on 71 outcomes among people with atopic eczema in UK primary care data

Using UK primary care data, investigators compared 3.6 million people with eczema to 16.8 million controls. They found eczema was strongly associated with hodgkin's lymphoma, alopecia areata, Crohn Disease, urticaria, coeliac disease, ulcerative colitis, autoimmune liver disease, and irritable bowel syndrome.

Association of air pollution and genetic risks with incidence of elderly-onset atopic dermatitis: A prospective cohort study

A UK Biobank study found both air pollution and genetics independently increased the risk of elderly-onset AD, but pollutants had a stronger effect than genetic predisposition.

Other useful dermatology journal entries published in the past 2 years that Zirwas presented are reported 

Relevant disclosures for Zirwas include Galderma Laboratories, L.P, Regeneron Healthcare Solutions, GENZYME CORPORATION, Arcutis Biotherapeutics, Lilly USA, Novartis Pharmaceuticals Corporation, Dermavant Sciences, LEO Pharma, Verrica Pharmaceuticals, Incyte Corporation, AbbVie, and PFIZER.

Zirwas M. The Most Useful Journal Articles of the Last 2 Years. Presented at the 2025 New Wave Dermatology at Aventura, Florida.

Munayco Maldonado G, Foy V, Tai H, Chiesa Fuxench ZC. Variation in clinical presentation of pediatric-onset and adult-onset atopic dermatitis: a retrospective, single-center, chart review of adults with atopic dermatitis from the United States. 

Zeldin J, Chaudhary PP, Spathies J, et al. Exposure to isocyanates predicts atopic dermatitis prevalence and disrupts therapeutic pathways in commensal bacteria. 

. 2023;9(1):eade8898. doi:10.1126/sciadv.ade8898

Van Beek MJ, Swerlick RA, Daveluy S, et al. The 2023 Annual Report of DataDerm: The database of the American Academy of Dermatology. 

. 2024;91(5):904-909. doi:10.1016/j.jaad.2024.05.096

Matthewman J, Schultze A, Strongman H, et al. Cohort studies on 71 outcomes among people with atopic eczema in UK primary care data. 

. 2024;15(1):9573. Published 2024 Nov 6. doi:10.1038/s41467-024-54035-1

Gu X, Jing D, Xiao Y, et al. Association of air pollution and genetic risks with incidence of elderly-onset atopic dermatitis: A prospective cohort study. 

. 2023;253:114683. doi:10.1016/j.ecoenv.2023.114683

Videos

Zirwas shares top dermatology studies, highlights AD misdiagnosis, and reveals how pollution and fabrics may trigger adult-onset atopic dermatitis.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? 

Top 5 Healthcare Headlines for May 5- 11, 2025:

FDA Accepts Sparsentan (Filspari) sNDA for Focal Segmental Glomerulosclerosis

The FDA will review Travere Therapeutics’ application for full approval of sparsentan in FSGS, with an advisory committee meeting planned ahead of a January 2026 decision.

FDA Accepts BioCryst’s NDA for Berotralstat Oral Granules in Children With HAE

The FDA is evaluating berotralstat oral granules for pediatric hereditary angioedema, which could become the first oral preventive therapy for children under 12.

SURMOUNT-5: Tirzepatide (Zepbound) Proves Benefit over Semaglutide (Wegovy) for Obesity

Tirzepatide demonstrated superior weight loss outcomes compared with semaglutide in the SURMOUNT-5 trial for patients with obesity.

Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis

Crinecerfont lowered steroid requirements while maintaining hormone control in children with classic congenital adrenal hyperplasia, regardless of baseline characteristics.

Type 1 Diabetes Diagnosed in Adulthood Heightens Cardiovascular Risk

Adults diagnosed with type 1 diabetes face increased cardiovascular and all-cause mortality risks, regardless of age at diagnosis, according to long-term national data.

The recent healthcare updates include the FDA's acceptance of Travere Therapeutics' application for sparsentan in FSGS and BioCryst's NDA for berotralstat oral granules for pediatric HAE. The SURMOUNT-5 trial showed tirzepatide's superior weight loss benefits over semaglutide for obesity. Crinecerfont was found to reduce steroid use in children with congenital adrenal hyperplasia while maintaining hormone control. Additionally, adults diagnosed with type 1 diabetes face heightened cardiovascular and all-cause mortality risks, irrespective of the age at diagnosis.

An audio recap of the top 5 stories in healthcare news from the week of 05/05-05/11.



Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatology

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

HCPLive 5 Stories in Under 5: Week of 05/11

Stay updated with the latest healthcare breakthroughs, including weight loss treatments, pediatric therapies, and FDA approvals shaping the future of medicine.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 05/11

Williams discusses the complicated relationship between ophthalmologists and their work as well as the benefits and challenges of reaching out to underrepresented groups.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Dealing with Perfectionism and Reaching Underrepresented Patients with Ruth Williams, MD

Podcasts

Discover expert insights and practical guidance in psychiatry with The Gus Alva Perspective, our latest expert-led multimedia offering.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

The Gus Alva Perspective

The Gus Alva Perspective is a twice-monthly video podcast hosted by Gus Alva, MD, DFAPA, spotlighting the latest in psychiatry and mental health—offering breakdowns of the latest updates, expert insights, and a look behind the scenes at the annual 

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Introducing The Gus Alva Perspective, with Gus Alva, MD

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Associations were particularly strong for people with severe COPD.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Perceived Stress Worsens Outcomes in People With COPD

Zirwas outlines a 4-visit approach to diagnosing spongiotic dermatitis, helping dermatologists manage uncertain rashes more effectively.


The First 4 Visits When Treating Spongiotic Dermatitis, With Matthew Zirwas, MD

In this interview, Mona Shahriari, MD, and Raj Chovatiya, MD, PhD, touched on the evolving role of pharmacists and internal medicine doctors in atopic dermatitis.

Latest News

Methotrexate Effective as Alternative to Prednisone for Pulmonary Sarcoidosis

Lung Transplant Waitlist Outcomes Improved After 2023 Allocation System Change

The Top Dermatology Journal Entries in the Past 2 Years

The Top 5 Atopic Dermatitis Studies in the Past 2 Years, with Matthew Zirwas, MD

HCPLive 5 Stories in Under 5: Week of 05/11